The haemorrhagic stroke treatment market is anticipated to grow at a CAGR of 4.10% during the forecast period 2025-2034, driven by the increase in the prevalence of hemorrhagic stroke in patients suffering from hypertension, and a rise in the geriatric population and chronic diseases across the 8 major markets.
Base Year
Historical Period
Forecast Period
The market is significantly driven by the growing investments in research and development activities, leading to innovative therapies and improved patient outcomes.
The rising number of FDA approvals is bolstering market expansion by ensuring faster access to effective treatment therapies.
Strategic acquisitions by key market players are enabling companies to expand their product portfolios and enhance technological capabilities, driving market growth.
Compound Annual Growth Rate
4.1%
Value in USD Million
2025-2034
Haemorrhagic Stroke Treatment Market Outlook
*this image is indicative*
In haemorrhagic stroke, the brain suffers from severe damage causing compromised ability of body movement (depending on the affected region). Long-term outcome depends on the extent of brain damage and the early treatments among several other factors. However, taking precautionary measures and seeking early treatment can help minimise stroke-related brain damage. Hemorrhagic strokes occur when blood vessels in the brain rupture or leak, causing bleeding in or around the brain, accounting for about 20% of all strokes.
There are several kinds of hemorrhage including subarachnoid hemorrhage (SAH) referring to bleeding around the brain. It is often caused by the rupture of an aneurysm on the brain’s surface. Intracerebral hemorrhage (ICH) involves bleeding into the brain itself, commonly triggered by high blood pressure, making timely medical intervention crucial for recovery.
Rising Cases of Stroke Driving Market Growth
The market is primarily driven by the rising incidence of haemorrhagic strokes among people, especially young adults, and elderly individuals. As per the data released by the Centers for Disease Control and Prevention (CDC), it is estimated that more than 750,000 strokes take place in the USA every year. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked.
The rising numbers are demanding new treatment options and diagnostic solutions to treat and prevent the occurrence of this extremely life-threatening medical condition.
The market is witnessing significant approvals by the regulatory authorities to bring new and advanced treatments and diagnostic solutions into the market. For instance, in May 2024, the Food and Drug Administration (FDA) granted 510(k) clearance for Heuron ICH, an artificial intelligence (AI)-enabled software that is expected to facilitate timely detection and triage of intracranial hemorrhages. As per the claims by Heuron, the software provides an 86% sensitivity rate and an 88% specificity rate for intracranial hemorrhage. The FDA approval marks a significant milestone for the company positioning it highly in the United States market, and propelling market growth.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The EMR’s report titled “Haemorrhagic Stroke Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Segmentation by Route of Administration to Hold a Substantial Share of the Market
The injectable segment leads the market share by route of administration due to the rapid and direct delivery of medications into the bloodstream, ensuring faster therapeutic effects, which is critical in emergency stroke management. Injectable treatments, such as anticoagulants, clotting factor concentrates, and antihypertensives, are preferred in acute care settings where quick intervention is necessary to control bleeding and prevent further brain damage. Additionally, hospitals and stroke centers favour injectable treatments for their effectiveness in stabilising patients during the critical phases of haemorrhagic stroke treatment.
The United States leads the regional market share due to its advanced healthcare infrastructure, high prevalence of stroke cases, and significant investments in research and development. The regional dominance is driven by the technologically advanced healthcare infrastructure and the availability of innovative treatment options, such as minimally invasive surgical techniques and advanced pharmaceuticals. Additionally, strong support from government health initiatives and the presence of leading pharmaceutical companies in the region, contribute to the dominance. The high healthcare expenditure and well-established reimbursement policies further drive the growth of the market in the United States.
The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis and strategic initiatives by the leading players. The major companies in the market are as follows:
Established in 1839, and headquartered in Melsungen, Germany, B. Braun Melsungen AG is a leading medical and pharmaceutical company. It offers an extensive portfolio including surgical instruments, infusion therapy, and pain management solutions, focusing on enhancing patient safety and healthcare efficiency.
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer is a global pharmaceutical and life sciences company. Its product portfolio in the healthcare market includes prescription pharmaceuticals, consumer health products, and crop protection solutions, with a focus on innovations in cardiovascular, oncology, and women's health.
Established in 1996, Novartis is headquartered in Basel, Switzerland. The company is a major player in the global pharmaceutical market, specialising in innovative medicines, generic pharmaceuticals, and eye care products. Its portfolio addresses areas like oncology, immunology, neuroscience, and respiratory conditions.
Founded in 1849 and headquartered in New York City, Pfizer is a leading biopharmaceutical company. It is renowned for its extensive portfolio in the pharmaceutical market, offering treatments for various medical fields, including oncology, vaccines, internal medicine, and rare diseases, with a strong focus on innovative research.
Established in 1891, Merck & Co., Inc., headquartered in Kenilworth, New Jersey, is a global healthcare company. Its portfolio in the pharmaceutical market includes prescription medicines, vaccines, biologic therapies, and animal health products, with a focus on addressing cancer, infectious diseases, and chronic conditions like diabetes.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim International GmbH.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
